This page shows the latest acute coronary syndrome news and features for those working in and with pharma, biotech and healthcare.
or cardiovascular death in adult following an acute myocardial infarction or heart attack. ... In addition to Farxiga, AZ also has Brilinta (ticagrelor) in its cardiovascular, renal and metabolism (CVRM) franchise, which is approved for the treatment of
The drug is already approved for the treatment of acute coronary syndrome (ACS) and for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack. ... who have previously experienced an acute ischaemic
Results of the phase 3 THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. ... The drug is already approved for the treatment
In addition, the drug also demonstrated a 15% relative risk reduction in patients who had previously undergone a percutaneous coronary intervention (PCI), a procedure to open a blocked or narrowed coronary ... Brilinta is already approved to reduce the
territory. Meanwhile, next year, AZ is also expecting a phase 3 readout in the THALES trial of Brilinta as a treatment for in acute ischemic stroke and transient ischaemic attack, that ... patients undergoing interventions for acute coronary syndrome (ACS
antiplatelet drug Brilinta (ticagrelor) rose 22% to $1.32bn thanks to continued market penetration in the treatment of acute coronary syndrome (ACS) and high-risk post-myocardial infarction patients.
More from news
Approximately 7 fully matching, plus 52 partially matching documents found.
In one recent programme that we developed on behalf of AstraZeneca, we assessed the reasons for low adherence in patients with acute coronary syndrome (ACS) who had been prescribed Oral Antiplatelet
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be ... to save the lives of thousands of people
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
A good example would be in acute coronary syndrome (ACS) where there is data to suggest that approximately 350, 000 males in the USA currently suffer from this syndrome.
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...